Sign in

CIK 0000730272

  • Large accelerated filer

REPLIGEN CORP

Sign in to watch
Ticker
RGEN
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
042729386
Phone
+1 781-449-9560
Business address
41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM, MA, 02453
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$4,976,580
in 4 filings, $5.0M under 10b5-1 plans

Net −$4,976,580. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Pace of trading Bought Sold

Who's trading

90 days

  1. Loeillot Olivier −$5.0M Chief Executive Officer sold 37% of stake

Reading 100 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2026-10-06 Douglass Brian Robb CHIEF PRODUCT OFFICER Grant or award +700 8,685
2026-10-06 Douglass Brian Robb CHIEF PRODUCT OFFICER Grant or award · Stock Option (Right to Buy) +675 675
2026-05-07 Douglass Brian Robb CHIEF PRODUCT OFFICER Shares withheld for taxes −334 $126.43 $42K 7,985
2026-03-02 Douglass Brian Robb CHIEF PRODUCT OFFICER Shares withheld for taxes −221 $124.97 $28K 8,319
2025-12-31 Douglass Brian Robb CHIEF PRODUCT OFFICER Grant or award +2,288 8,540
2025-12-31 Douglass Brian Robb CHIEF PRODUCT OFFICER Grant or award · Stock Option (Right to Buy) +2,143 2,143

Page 1 of 1 · 6 trades